Акушерство и Гинекология Санкт-Петербурга. 2019; : 54-58
Состояние овариального резерва после применения различных видов медикаментозной терапии миомы матки (обзор литературы)
Аннотация
Обзор данных литературы по проблеме состояния овариального резерва при применении различных вариантов консервативного лечения миомы матки у женщин репродуктивного возраста.
Список литературы
1. Stewart E.A., Cookson C.L., Gandolfo R.A. et al. Epidemiology of uterine fibroids: a systematic review. BJOG. 2017; 124 (10): 1501–1512. doi: 10.1111/1471-0528.14640 (дата обращения 01.09.2019).
2. Адамян Л.В., Серов В.Н., Сухих Г.Т., Филиппов О.С. Клинические рекомендации. Акушерство и гинекология. Миома матки: диагностика, лечение и реабилитация. Проблемы репродукции. 2017; (6): 503–552.
3. Ярмолинская М.И., Цыпурдеева А.А., Долинский А.К., Коган И.Ю., Баранов В.С., Кветной И.М. и др. Миома матки. Этиология, патогенез, принципы диагностики: пособие для врачей. СПб.: Н-Л; 2013. С. 78.
4. Boosz A.S., Reimer P., Matzko M. et al. The conservative and interventional treatment of fibroids. Dtsch Arztebl. Int. 2014; 22 (111): 877–883. doi: 10.3238/arztebl.2014.0877 (дата обращения 01.09.2019).
5. Pavone D., Clemenza S., Sorbi F. et al. Epidemiology and Risk Factors of Uterine Fibroids. Best Pract. Res. Clin.Obstet. Gynaecol. 2018; 46: 3–11. doi: 10.1016/j.bpobgyn.2017.09.004 (дата обращения 01.09.2019).
6. Yuan H., Wang C., Wang D. et al. Comparing the effect of laparoscopic supra-cervical and total hysterectomy for uterine fibroids on ovarian reserve by assessing serum anti-mullerian hormone levels: a prospective cohort study. J Minim Invasive Gynecol. 2015; 22 (4): 637–641. doi: 10.1016/j.jmig.2015.01.025 (дата обращения 01.09.2019).
7. Vilos G.A., Allaire C., Laberge P.Y. et al. The management of uterine leiomyomas. J. Obstet. Gynaecol. Can. 2015; 37 (2): 157–178. doi: 10.1016/S1701-2163(15)30338-8 (дата обращения 01.09.2019).
8. Jeong J.H., Hong G.P., Kim Y.R. et al. Expulsion of fibroids to the endometrial cavity after magnetic resonance imaging-guided high intensity focused ultrasound surgery (MRgFUS) treatment of intramural uterine fibroids. J. Menopausal. Med. 2016; 22: 139–145.
9. Лебедев В.А., Давыдов А.И., Пашков В.М. Спорные и нерешенные вопросы лечения и профилактики миомы матки у больных репродуктивного периода. Трудный пациент. 2013; 11 (8–9): 14–19.
10. Можейко Л.Ф., Гузей И.А., Белонович К.В. Миома матки: этиопатогенез, течение беременности и родов. Охрана материнства и детства. 2014; 1 (23): 99–103.
11. Jain D. Mifepristone Therapy in Symptomatic Leiomyomata Using a Variable Dose Pattern with a FavourableOutcome. J. Midlife Health. 2018; 9 (2): 65–71.
12. Koskas M., Chabbert-Buffet N., Douvier S. et al. Role of medical treatment for symptomatic leiomyoma management in premenopausal women. J. Gynecol. Obstet. Biol. Reprod. (Paris). 2011; 40: 858–874.
13. Фаткуллин И.Ф., Баканова А.Р., Илизарова Н.А., Галеев А.А. Новые возможности лечения миомы матки у женщин при нарушении репродуктивной функции. Доктор.Ру. 2016; 8–9 (125–126): 32–37.
14. Moradan S. Gonadotropin-releasing Hormone Agonist Plus Aromatase Inhibitor in the Treatment of Uterine Leiomyoma in Near Menopause Patient: A Case Series Study. J. Menopausal Med. 2018; 24 (1): 62–66.
15. Donnez J., Tomaszewski J., Vázquez F. et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N. Engl. J. Med. 2012; 366: 421–432.
16. Жемчужина Т.Ю. Миома матки: принципы лечения. Учебно-методическое пособие. СПб.: РИЦ ПСПбГМУ; 2017. C. 76.
17. Oesterreich S., Henry N.L., Kidwell K.M. et al. Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover. Breast Cancer Res. Treat. 2015; 154 (2): 263–273.
18. Ткаченко Л.В., Свиридова Н.И. Роль агонистов гонатропин-рилизинг-гормана в комплексной терапии гиперпластических процессов репродуктивных органов. Журнал акушерства и женских болезней. 2014; LXIII (2): 6–11.
19. Давыдов А.И., Лебедев В.А., Пашков В.М. и др. Принципы терапии и профилактики рецидивов миомы матки у больных репродуктивного периодов: реальность и перспективы. Вопросы гинекологии, акушерства и перинатологии. 2013; 12 (1): 35–42.
20. Lusher S.J., Raaijmakers H.C., Vu-Pham D. et al. Structural basis for agonism and antagonism for a set of chemically related progesterone receptor modulators. J. Biol. Chem. 2011; 286 (40): 35079–35086.
21. Bouchard P. Selective progesterone receptor modulators: a class with multiple actions and applications in reproductive endocrinology, and gynecology. Journal Gynecol. Endocrinol. 2014; 30 (10): 683–684. doi: 10.3109/09513590.2014.950647 (дата обращения 01.09.2019).
22. Wagenfeld A., Saunders P.T., Whitaker L., Critchley H.O. Selective progesterone receptor modulators (SPRMs): progesterone receptor action, mode of action on the endometrium and treatment options in gynecological therapies. Expert. Opin. Ther. Targets. 2016; 20 (9): 1045–1054.
23. Беженарь В.Ф., Комличенко Э.В., Ярмолинская М.И. и др. Инновационные подходы к восстановлению репродуктивной функции у больных с миомой матки. Акушерство и гинекология. 2016; (1): 80–87.
24. Bouchard P., Chabbert-Buffet N., Fauser B.C. Selective progesterone receptor modulators in reproductive medicine: pharmacology, clinical efficacy and safety. Fertil. Steril. 2011; 96 (5): 1175–1189.
25. Donnez J., Arriagada P., Donnez O., Dolmans M.M. Current management of myomas: the place of medical therapy with the advent of selective progesterone receptor modulators. Curr. Opin. Obstet. Gynecol. 2015; 27 (6): 422–431.
26. Usluogullari B., Duvan C., Usluogullari C. Use of aromatase inhibitors in practice of gynecology. J. Ovarian Res. 2015; 8 (4). doi: 10.1186/s13048-015-0131-9 (дата обращения 01.09.2019).
27. Jiang W., Shen Q., Chen M. et al. Levonorgestrel-releasing intrauterine system use in premenopausal women with symptomatic uterine leiomyoma: a systematic review. Steroids. 2014; 86: 69–78. doi: 10.1016/j.steroids.2014.05.002 (дата обращения 01.09.2019).
28. Гаджиева М.Ш., Омаров Н.С. Комплексный подход к снижению риска послеоперационных осложнений у больных с миомой матки и дисбактериозом влагалища. Успехи современной науки. 2016; 1 (4): 148–154.
29. Yuk J.S., Song J.Y., Lee J.H. et al. levonorgestrel-releasing intrauterine systems versusoral cyclic medroxyprogesterone acetate in endometrial hyperplasia therapy: a meta-analysis. Ann. Surg. Oncol. 2017; 24 (5): 1322–1329. doi: 10.1245/s10434-016-5699-9 (дата обращения 01.09.2019).
30. Lethaby A., Hussain M., Rishworth J.R. et al. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding. Cochrane Database Syst. Rev. 2015; 30 (4): CD002126. doi: 10.1002/14651858.CD002126.pub3 (дата обращения 01.09.2019).
31. Nelson A.L. Levonorgestrel-releasing intrauterine system (LNG-IUS 12) for prevention of pregnancy for up to five years. Expert. Rev. Clin. Pharmacol. 2017; 10 (8): 833–842. doi: 10.1080/17512433.2017.1341308 (дата обращения 01.09.2019).
32. Carbonell J.L., Acosta R., Pérez Y. et al. Safety and effectiveness of different dosage of mifepristone for the treatment of uterine fibroids: a double-blind randomized clinical trial. Int. J. Womens Health. 2013; 19 (5): 115–124.
33. Esteve J.L.C., Acosta R., Pérez Y. et al. Treatment of uterine myoma with 5 or 10mg mifepristone daily during 6 months, post-treatment evolution over 12 months: double-blind randomised clinical trial. Eur. J. Obstet. Gynecol. 2012; 161: 202–208.
34. Kapur A., Angomchanu R., Dey M. et al. Efficacy of use of long-term, low-dose mifepristone for the treatment of fibroids. J. Obstet. Gynaecol. India. 2016; 66 (1): 494–498.
35. Леваков С.А., Кедрова А.Г., Нечаева О.Е. и др. Опыт консервативного лечения больных с миомой матки. Акушерство и гинекология. 2014; (12): 83–90.
36. Schreiber C.A., Sober S., Ratcliffe S., Creinin M.D. Ovulation resumption after medical abortion with mifepristone and misoprostol. Contraception. 2011; 84 (3): 230–233.
37. Mauro А., Martelli A., Berardinelli P. et al. Effect of antiprogesterone RU486 on VEGF expression and blood vessel remodeling on ovarian follicles before ovulation. PLoSOne. 2014; 9 (4): 95910.
Obstetrics and Gynaecology of Saint-Petersburg. 2019; : 54-58
State of ovarian reserve after various types of medical therapy of uterine fibroids (review)
Abstract
The review provides an overview of literature data on the state of ovarian reserve in the application of various options for conservative treatment of uterine fibroids in women of reproductive age.
References
1. Stewart E.A., Cookson C.L., Gandolfo R.A. et al. Epidemiology of uterine fibroids: a systematic review. BJOG. 2017; 124 (10): 1501–1512. doi: 10.1111/1471-0528.14640 (data obrashcheniya 01.09.2019).
2. Adamyan L.V., Serov V.N., Sukhikh G.T., Filippov O.S. Klinicheskie rekomendatsii. Akusherstvo i ginekologiya. Mioma matki: diagnostika, lechenie i reabilitatsiya. Problemy reproduktsii. 2017; (6): 503–552.
3. Yarmolinskaya M.I., Tsypurdeeva A.A., Dolinskii A.K., Kogan I.Yu., Baranov V.S., Kvetnoi I.M. i dr. Mioma matki. Etiologiya, patogenez, printsipy diagnostiki: posobie dlya vrachei. SPb.: N-L; 2013. S. 78.
4. Boosz A.S., Reimer P., Matzko M. et al. The conservative and interventional treatment of fibroids. Dtsch Arztebl. Int. 2014; 22 (111): 877–883. doi: 10.3238/arztebl.2014.0877 (data obrashcheniya 01.09.2019).
5. Pavone D., Clemenza S., Sorbi F. et al. Epidemiology and Risk Factors of Uterine Fibroids. Best Pract. Res. Clin.Obstet. Gynaecol. 2018; 46: 3–11. doi: 10.1016/j.bpobgyn.2017.09.004 (data obrashcheniya 01.09.2019).
6. Yuan H., Wang C., Wang D. et al. Comparing the effect of laparoscopic supra-cervical and total hysterectomy for uterine fibroids on ovarian reserve by assessing serum anti-mullerian hormone levels: a prospective cohort study. J Minim Invasive Gynecol. 2015; 22 (4): 637–641. doi: 10.1016/j.jmig.2015.01.025 (data obrashcheniya 01.09.2019).
7. Vilos G.A., Allaire C., Laberge P.Y. et al. The management of uterine leiomyomas. J. Obstet. Gynaecol. Can. 2015; 37 (2): 157–178. doi: 10.1016/S1701-2163(15)30338-8 (data obrashcheniya 01.09.2019).
8. Jeong J.H., Hong G.P., Kim Y.R. et al. Expulsion of fibroids to the endometrial cavity after magnetic resonance imaging-guided high intensity focused ultrasound surgery (MRgFUS) treatment of intramural uterine fibroids. J. Menopausal. Med. 2016; 22: 139–145.
9. Lebedev V.A., Davydov A.I., Pashkov V.M. Spornye i nereshennye voprosy lecheniya i profilaktiki miomy matki u bol'nykh reproduktivnogo perioda. Trudnyi patsient. 2013; 11 (8–9): 14–19.
10. Mozheiko L.F., Guzei I.A., Belonovich K.V. Mioma matki: etiopatogenez, techenie beremennosti i rodov. Okhrana materinstva i detstva. 2014; 1 (23): 99–103.
11. Jain D. Mifepristone Therapy in Symptomatic Leiomyomata Using a Variable Dose Pattern with a FavourableOutcome. J. Midlife Health. 2018; 9 (2): 65–71.
12. Koskas M., Chabbert-Buffet N., Douvier S. et al. Role of medical treatment for symptomatic leiomyoma management in premenopausal women. J. Gynecol. Obstet. Biol. Reprod. (Paris). 2011; 40: 858–874.
13. Fatkullin I.F., Bakanova A.R., Ilizarova N.A., Galeev A.A. Novye vozmozhnosti lecheniya miomy matki u zhenshchin pri narushenii reproduktivnoi funktsii. Doktor.Ru. 2016; 8–9 (125–126): 32–37.
14. Moradan S. Gonadotropin-releasing Hormone Agonist Plus Aromatase Inhibitor in the Treatment of Uterine Leiomyoma in Near Menopause Patient: A Case Series Study. J. Menopausal Med. 2018; 24 (1): 62–66.
15. Donnez J., Tomaszewski J., Vázquez F. et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N. Engl. J. Med. 2012; 366: 421–432.
16. Zhemchuzhina T.Yu. Mioma matki: printsipy lecheniya. Uchebno-metodicheskoe posobie. SPb.: RITs PSPbGMU; 2017. C. 76.
17. Oesterreich S., Henry N.L., Kidwell K.M. et al. Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover. Breast Cancer Res. Treat. 2015; 154 (2): 263–273.
18. Tkachenko L.V., Sviridova N.I. Rol' agonistov gonatropin-rilizing-gormana v kompleksnoi terapii giperplasticheskikh protsessov reproduktivnykh organov. Zhurnal akusherstva i zhenskikh boleznei. 2014; LXIII (2): 6–11.
19. Davydov A.I., Lebedev V.A., Pashkov V.M. i dr. Printsipy terapii i profilaktiki retsidivov miomy matki u bol'nykh reproduktivnogo periodov: real'nost' i perspektivy. Voprosy ginekologii, akusherstva i perinatologii. 2013; 12 (1): 35–42.
20. Lusher S.J., Raaijmakers H.C., Vu-Pham D. et al. Structural basis for agonism and antagonism for a set of chemically related progesterone receptor modulators. J. Biol. Chem. 2011; 286 (40): 35079–35086.
21. Bouchard P. Selective progesterone receptor modulators: a class with multiple actions and applications in reproductive endocrinology, and gynecology. Journal Gynecol. Endocrinol. 2014; 30 (10): 683–684. doi: 10.3109/09513590.2014.950647 (data obrashcheniya 01.09.2019).
22. Wagenfeld A., Saunders P.T., Whitaker L., Critchley H.O. Selective progesterone receptor modulators (SPRMs): progesterone receptor action, mode of action on the endometrium and treatment options in gynecological therapies. Expert. Opin. Ther. Targets. 2016; 20 (9): 1045–1054.
23. Bezhenar' V.F., Komlichenko E.V., Yarmolinskaya M.I. i dr. Innovatsionnye podkhody k vosstanovleniyu reproduktivnoi funktsii u bol'nykh s miomoi matki. Akusherstvo i ginekologiya. 2016; (1): 80–87.
24. Bouchard P., Chabbert-Buffet N., Fauser B.C. Selective progesterone receptor modulators in reproductive medicine: pharmacology, clinical efficacy and safety. Fertil. Steril. 2011; 96 (5): 1175–1189.
25. Donnez J., Arriagada P., Donnez O., Dolmans M.M. Current management of myomas: the place of medical therapy with the advent of selective progesterone receptor modulators. Curr. Opin. Obstet. Gynecol. 2015; 27 (6): 422–431.
26. Usluogullari B., Duvan C., Usluogullari C. Use of aromatase inhibitors in practice of gynecology. J. Ovarian Res. 2015; 8 (4). doi: 10.1186/s13048-015-0131-9 (data obrashcheniya 01.09.2019).
27. Jiang W., Shen Q., Chen M. et al. Levonorgestrel-releasing intrauterine system use in premenopausal women with symptomatic uterine leiomyoma: a systematic review. Steroids. 2014; 86: 69–78. doi: 10.1016/j.steroids.2014.05.002 (data obrashcheniya 01.09.2019).
28. Gadzhieva M.Sh., Omarov N.S. Kompleksnyi podkhod k snizheniyu riska posleoperatsionnykh oslozhnenii u bol'nykh s miomoi matki i disbakteriozom vlagalishcha. Uspekhi sovremennoi nauki. 2016; 1 (4): 148–154.
29. Yuk J.S., Song J.Y., Lee J.H. et al. levonorgestrel-releasing intrauterine systems versusoral cyclic medroxyprogesterone acetate in endometrial hyperplasia therapy: a meta-analysis. Ann. Surg. Oncol. 2017; 24 (5): 1322–1329. doi: 10.1245/s10434-016-5699-9 (data obrashcheniya 01.09.2019).
30. Lethaby A., Hussain M., Rishworth J.R. et al. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding. Cochrane Database Syst. Rev. 2015; 30 (4): CD002126. doi: 10.1002/14651858.CD002126.pub3 (data obrashcheniya 01.09.2019).
31. Nelson A.L. Levonorgestrel-releasing intrauterine system (LNG-IUS 12) for prevention of pregnancy for up to five years. Expert. Rev. Clin. Pharmacol. 2017; 10 (8): 833–842. doi: 10.1080/17512433.2017.1341308 (data obrashcheniya 01.09.2019).
32. Carbonell J.L., Acosta R., Pérez Y. et al. Safety and effectiveness of different dosage of mifepristone for the treatment of uterine fibroids: a double-blind randomized clinical trial. Int. J. Womens Health. 2013; 19 (5): 115–124.
33. Esteve J.L.C., Acosta R., Pérez Y. et al. Treatment of uterine myoma with 5 or 10mg mifepristone daily during 6 months, post-treatment evolution over 12 months: double-blind randomised clinical trial. Eur. J. Obstet. Gynecol. 2012; 161: 202–208.
34. Kapur A., Angomchanu R., Dey M. et al. Efficacy of use of long-term, low-dose mifepristone for the treatment of fibroids. J. Obstet. Gynaecol. India. 2016; 66 (1): 494–498.
35. Levakov S.A., Kedrova A.G., Nechaeva O.E. i dr. Opyt konservativnogo lecheniya bol'nykh s miomoi matki. Akusherstvo i ginekologiya. 2014; (12): 83–90.
36. Schreiber C.A., Sober S., Ratcliffe S., Creinin M.D. Ovulation resumption after medical abortion with mifepristone and misoprostol. Contraception. 2011; 84 (3): 230–233.
37. Mauro A., Martelli A., Berardinelli P. et al. Effect of antiprogesterone RU486 on VEGF expression and blood vessel remodeling on ovarian follicles before ovulation. PLoSOne. 2014; 9 (4): 95910.
